Expression of chemokine ligand-10, T cells in peripheral blood of children with hand, foot and mouth disease and their correlation with prognosis

doi:10.3877/cma.j.issn.1674-1358.2019.03.012

Abstract

Abstract:

Objective

To investigate the expression of chemokine ligand-10 (CXCL-10) in peripheral blood of children with hand, foot and mouth disease (HFMD), and the correlation between T lymphocyte subsets and related cytokines and prognosis in children with HFMD.

Methods

From April 2016 to May 2017, a total of 60 children with HFMD were divided into severe group (10 cases) and mild group (50 cases) according to the diagnosis criteria, and were divided into good prognosis group (58 cases) and poor prognosis group (2 cases) according to the results of follow-up. While 52 infants with normal physical examination were selected as control group. The expression level of CXCL-10 in the peripheral blood of the two groups was detected by ELISA, the T-lymphocyte subpopulation of peripheral blood was detected by flow cytometry, and the levels of IL-17, IL-22, IL-23 and TNF-α in peripheral blood were detected by ELISA, respectively.

Results

The levels of CXCL-10, IL-17, IL-22, IL-23 and TNF-α in peripheral blood of children in severe group were significantly higher than those of control group and mild group (all P < 0.001). The levels of CXCL-10, IL-17, IL-22, IL-23 and TNF-α of children in mild group were higher than those in control group (all P < 0.005). CD3⁺ T, CD4⁺ T and CD8⁺ T lymphocytes in peripheral blood of children in severe group were significantly lower than those of mild group and control group (all P < 0 05). There was significant difference in the proportion of CD3⁺ T, CD4⁺ T, CD8⁺ T and CD4⁺/CD8⁺ lymphocytes between children in mild group and control group (all P < 0.05). Pearson correlation coefficient analysis showed that the expression of CXCL-10 in peripheral blood of children with HFMD were negatively correlated with the expression of CD3⁺, CD4⁺, CD8⁺ T and CD4⁺/CD8⁺ (r =-0.609, -0.714, -0.514, -0.524; P = 0.014, 0.023, 0.001, 0.006). The levels of IL-17, IL-22, IL-23 and TNF-α in peripheral blood of children with HFMD were positively correlated with the levels of CXCL-10 (r = 0.519, 0.0.473, 0.418, 0.459; P = 0.002, 0.006, 0.009, 0.007). The expression of CXCL-10 in peripheral blood of children with poor prognosis was significantly higher than that of children with good prognosis (t = 2.055, P = 0.044). The proportion of CD3⁺ T, CD4⁺ T and CD8⁺ T lymphocytes in peripheral blood of children with poor prognosis were significantly lower than those of children with good prognosis, with significant differences (t = 2.508, P = 0.015; t = 3.830, P < 0.0001; t = 2.222, P = 0.030).

Conclusions

The detection of peripheral blood CXCL-10 and T-lymphocyte subsets in children with HFMD is of great value to monitor and judge the prognosis.

Key words: Hand, foot and mouth disease, Chemokine ligand-10, T lymphocyte subset

Wei Zhang, Haomiao Sun, Jie Wang. Expression of chemokine ligand-10, T cells in peripheral blood of children with hand, foot and mouth disease and their correlation with prognosis[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(03): 239-244.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.03.012

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I03/239

Figures/Tables 4

References 25

[1]	周亮, 马青山. T淋巴细胞免疫功能与儿童哮喘[J]. 河北医药,2016,38(20):3169-3172.
[2]	《疑难病杂志》编辑部. 手足口病诊疗技术指南[J]. 疑难病杂志,2009,8(3):156-156.
[3]	陈苏, 杜潘艳, 郑红, 等. 不同肠道病毒感染手足口病患儿病毒载量及临床特征对比分析[J]. 中国全科医学,2016,19(18):2211-2215.
[4]	王宇婧, 程邦宁. 多种肠道病毒引起手足口病细胞免疫功能比较[J]. 安徽医科大学学报,2016,51(12):1836-1838.
[5]	王彩英, 李建国, 于晓黎, 等. 手足口病重症患儿医院感染的干预措施分析[J]. 中华医院感染学杂志,2016,26(19):4518-4520.
[6]	高芳, 刘蕾. 手足口病患儿外周血白细胞计数,空腹血糖,超敏C反应蛋白水平变化[J]. 山东医药,2016,56(3):66-67.
[7]	王晓波, 杜潘艳, 赵玉萍, 等. 手足口病重症患儿营养素水平与病情的相关性分析[J]. 中国免疫学杂志,2016,32(3):414-416.
[8]	沈嬿, 陈中新, 胡建国, 等. EV71-IgM抗体检测在婴幼儿肠道病毒感染早期诊治和防控中的意义[J]. 中华全科医学,2018,16(5):708-711.
[9]	孔慧, 都鹏飞, 卢娟. 柯萨奇病毒A组16型与小鼠病毒性心肌炎的关联性及其药物干预研究[J]. 安徽医药,2017,21(9):1586-1589.
[10]	宋蕾, 荣诗阔, 凡亚运, 等. 趋化因子IP10在结直肠癌组织中的表达及临床意义[J]. 宁夏医学杂志,2016,38(10):872-874.
[11]	施栋梁, 林青. 趋化因子CXCL9, CXCL10, CXCL11与狼疮肾炎相关性研究进展[J]. 免疫学杂志,2016,32(7):630-633.
[12]	陈莉婷, 彭敏. 人乳头瘤病毒16, 18感染与宫颈病变组织γ干扰素及白细胞介素-10表达的关系分析[J]. 中国妇幼保健,2017,32(3):466-469.
[13]	黄志华, 孙淑君, 唐湘祁. 脂质运载蛋白2在中枢神经系统疾病中的不同作用[J]. 医学临床研究,2017,34(7):1325-1328.
[14]	施华球, 谢瑞莲. 白介素1受体相关激酶1在乳腺癌紫杉醇耐受患者治疗中的作用机制研究[J]. 中国全科医学,2017,20(2):165-171.
[15]	苏文芳, 陈梅英, 郑振光. T淋巴细胞亚群, NK细胞及B细胞在急性原发免疫性血小板减少症患儿外周血中的表达[J]. 海南医学,2016,27(22):3656-3658.
[16]	浦飞飞, 邵增务. T淋巴细胞免疫球蛋白黏蛋白-3在肿瘤免疫中的研究进展[J]. 肿瘤防治研究,2017,44(10):701-705.
[17]	段炤, 林智平, 刘青, 等. CD4⁺CD25⁺调节性T淋巴细胞与辅助性T淋巴细胞17在川崎病发病机制中的作用[J]. 中华实用儿科临床杂志,2017,32(9):652-655.
[18]	葛宽雪, 高伟华, 向晓星. 辅助性T淋巴细胞17和调节性T淋巴细胞及其平衡改变与自身免疫性肝炎的关系[J]. 临床肝胆病杂志,2018,34(7):212-215.
[19]	夏晓玲, 汤玮, 孙亮亮, 等. 甲状腺相关性眼病患者外周血CD4⁺, CD8⁺ T细胞百分比及细胞表面程序性死亡蛋白1表达的改变及其意义[J]. 第二军医大学学报,2016,37(6):704-710.
[20]	张楠, 李海燕, 李玲. CD8⁺, CD4⁺ T细胞免疫功能与尖锐湿疣患者HPV感染的相关性分析[J]. 临床和实验医学杂志,2017,16(20):2057-2059.
[21]	荆凡辉, 吕玮, 李太生. HIV感染者免疫功能重建新视角: CD4/CD8比值[J]. 中国艾滋病性病,2018,24(6):643-646.
[22]	虞忻, 王霞芳, 唐佩军, 等. 细菌性肺炎患者外周血中免疫抑制性细胞亚群分布特性及其临床意义[J]. 结核病与肺部健康杂志,2016,5(1):47-51.
[23]	赵欣楠, 王晓非. CD3⁺CD4^－CD8^－ T细胞与自身免疫性疾病的研究进展[J]. 医学综述,2017,23(13):2522-2525.
[24]	Zhou JF, Chen ZY, Yang SM, et al. Clinical features and peripheral blood T lymphocyte subsets in hand, foot, and mouth disease according to different pathogens[J]. Indian J Pediatr,2017,84(2):124- 127.
[25]	孙林春, 张利, 张兰芳. 手足口病患儿外周血T淋巴细胞活化状态[J]. 广东医学,2016,37(21):3251-3254.

组别	例数	CXCL-10（ng/L）	IL-17（pg/ml）	IL-22（pg/ml）	IL-23（pg/ml）	TNF-α（pg/ml）
对照组	52	145.12 ± 32.71	12.29 ± 1.42	14.97 ± 3.64	17.42 ± 3.84	1.85 ± 0.26
轻症组	50	158.15 ± 21.95	21.36 ± 2.10	35.91 ± 5.48	30.19 ± 3.32	2.06 ± 0.54
重症组	10	178.47 ± 22.09	38.92 ± 6.77	56.37 ± 8.19	46.78 ± 6.07	3.72 ± 0.97
F值	?	7.227	490.203	396.343	302.637	63.113
P值	?	0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	CXCL-10（ng/L）	IL-17（pg/ml）	IL-22（pg/ml）	IL-23（pg/ml）	TNF-α（pg/ml）
对照组	52	145.12 ± 32.71	12.29 ± 1.42	14.97 ± 3.64	17.42 ± 3.84	1.85 ± 0.26
轻症组	50	158.15 ± 21.95	21.36 ± 2.10	35.91 ± 5.48	30.19 ± 3.32	2.06 ± 0.54
重症组	10	178.47 ± 22.09	38.92 ± 6.77	56.37 ± 8.19	46.78 ± 6.07	3.72 ± 0.97
F值	?	7.227	490.203	396.343	302.637	63.113
P值	?	0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	CD3⁺（%）	CD4⁺（%）	CD8⁺（%）	CD4⁺/CD8⁺
对照组	52	67.26 ± 6.18	42.13 ± 5.71	24.32 ± 3.38	1.60 ± 0.21
轻症组	50	62.03 ± 10.47	38.29 ± 4.87	22.64 ± 4.78	1.75 ± 0.41
重症组	10	47.32 ± 8.26	29.32 ± 6.74	17.24 ± 2.18	1.42 ± 0.28
F值	?	23.680	24.663	13.381	4.317
P值	?	<0.001	<0.001	<0.001	0.016

组别	例数	CD3⁺（%）	CD4⁺（%）	CD8⁺（%）	CD4⁺/CD8⁺
对照组	52	67.26 ± 6.18	42.13 ± 5.71	24.32 ± 3.38	1.60 ± 0.21
轻症组	50	62.03 ± 10.47	38.29 ± 4.87	22.64 ± 4.78	1.75 ± 0.41
重症组	10	47.32 ± 8.26	29.32 ± 6.74	17.24 ± 2.18	1.42 ± 0.28
F值	?	23.680	24.663	13.381	4.317
P值	?	<0.001	<0.001	<0.001	0.016

组别	例数	CXCL10（ng/L）	CD3⁺ T（%）	CD4⁺ T（%）	CD8⁺ T（%）	CD4⁺/CD8^{+ T}
预后良好组	58	160.25 ± 12.17	61.32 ± 5.98	40.02 ± 2.72	21.34 ± 2.87	1.68 ± 0.25
预后不良组	2	178.15 ± 8.01	50.41 ± 9.16	32.38 ± 4.95	16.64 ± 5.69	1.54 ± 0.37
t值	?	2.055	2.508	3.830	2.222	0.771
P值	?	0.044	0.015	<0.001	0.030	0.444
组别	例数	IL-17（pg/ml）	IL-22（pg/ml）	IL-23（pg/ml）	TNF-α（pg/ml）
预后良好组	58	20.38 ± 5.23	34.62 ± 5.71	28.65 ± 5.68	1.98 ± 0.36
预后不良组	2	38.96 ± 6.81	57.04 ± 7.62	47.05 ± 6.57	3.82 ± 1.06
t值	?	4.910	5.423	4.491	6.679
P值	?	<0.001	<0.001	<0.001	<0.001

Please choose a citation manager

Content to export